Clopidogrel plus aspirin for 21 days provides favorable net clinical benefit in minor ischemic strokeDual antiplatelet therapy shows mixed results for stroke prevention

This Bayesian network meta-analysis synthesized data from 8 trials involving a large population of 50,349 adults. The study specifically targeted patients with acute non-cardioembolic minor ischemic stroke, defined by an NIHSS score of less than or equal to 5, or those presenting with high-risk transient ischemic attack (TIA). The analysis evaluated various dual antiplatelet therapy (DAPT) strategies, including aspirin monotherapy, clopidogrel plus aspirin for 21 or 90 days, ticagrelor plus aspirin for 21 or 30 days, and ticagrelor monotherapy, comparing these against aspirin monotherapy as the primary comparator.

The primary outcome measured was the incidence of recurrent ischemic stroke at 90 days. The analysis revealed that ticagrelor plus aspirin for 21 days compared to aspirin monotherapy resulted in an odds ratio (OR) of 0.55 (95% CrI 0.46-0.66). Similarly, clopidogrel plus aspirin for 21 days compared to aspirin monotherapy showed a significant reduction in recurrent stroke with an OR of 0.68 (95% CrI 0.57-0.81). These results suggest that both DAPT regimens are more effective than aspirin monotherapy in preventing recurrent events in the 90-day window.

Secondary outcomes focused on safety, specifically the rate of major bleeding. The data indicated a significant increase in major bleeding for ticagrelor plus aspirin for 21 days compared to aspirin monotherapy, with an OR of 1.80 (95% CrI 1.20-2.70). For ticagrelor plus aspirin for 30 days, the risk of major bleeding was even higher, with an OR of 2.10 (95% CrI 1.50-2.94). In contrast, clopidogrel plus aspirin for 21 days showed no significant difference in major bleeding compared to aspirin monotherapy, with an OR of 1.05 (95% CrI 0.70-1.58).

When comparing these results to the broader clinical landscape, the data highlights a distinct trade-off between efficacy and safety. While ticagrelor-based regimens provide the highest level of protection against recurrent ischemic stroke, they carry a substantially higher risk of major bleeding than clopidogrel-based regimens. The clopidogrel plus aspirin for 21 days regimen appears to offer a more balanced profile, providing significant protection against stroke while maintaining a safety profile similar to aspirin monotherapy.

Methodological limitations for this analysis include the fact that it is a Bayesian network meta-analysis, which relies on the underlying data of the 8 included trials. Specific details regarding the study settings and individual trial designs were not reported in the synthesis. Furthermore, the lack of reported data on other adverse events or specific reasons for treatment discontinuation limits the full scope of the safety profile.

Clinically, these findings suggest that for patients with minor ischemic stroke or high-risk TIA, the choice of DAPT depends on the individual's risk profile. Clopidogrel plus aspirin for 21 days is identified as the most favorable net clinical benefit because it reduces stroke risk without significantly increasing bleeding risk compared to monotherapy. Conversely, ticagrelor plus aspirin for 21 days may be reserved for patients where the risk of recurrent stroke is exceptionally high and can outweigh the increased risk of major bleeding. Questions remain regarding the long-term outcomes beyond 90 days and the specific impact of ticagrelor monotherapy compared to other DAPT regimens in this specific population.